Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Part 1: Emilio Torres-Netto, WOC 2020 – Corneal Cross-linking for Progressive Keratoconus

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 31st 2020

Emilio Torres-Netto (CABMM, University of Zürich, Zürich, Switzerland) shares his thoughts on the rationale of corneal cross-linking in progressive keratoconus and the reasons for the lack of long-term data on corneal cross-linking to date.

1. What is the rationale for corneal cross-linking in progressive keratoconus? (0:09)
2. Before your study, how much long-term data on the use of corneal cross-linking were available? (0:57)

Disclosures: Emilio Torres-Netto has no financial or non-financial relationships or activities to declare in relation to this video.

touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Commissioned, edited and funded by Touch Medical Media
Published: 31 July 2020

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup